Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

AstraZeneca Initially Pays $100M for Rigel’s Late-Stage RA Drug

Rigel is eligible to over $1 billion in milestones related to this oral Syk inhibitor, poised to enter Phase III trials.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

The Price of BRCA Testing

Is getting a genetic test worth the multi-thousand dollar price?

Suggest a Poll